Please join our Feb. 17 OHDSI Community Call (11 am ET) to hear about the Objectives and Key Results for some of our OHDSI workgroups, as well to join a mini-journal club session on this recent Lancet publication.
๐๐๐๐๐๐๐๐๐: ๐๐๐ ๐๐๐๐
Due to ongoing technical issues within the OHDSI tenant, we have generated a new temporary link for our upcoming sessions. Please find this link on our community calls page: Community Calls 2026 โ OHDSI
๐๐๐ญ๐ข๐จ๐ง ๐๐๐ช๐ฎ๐ข๐ซ๐๐: Please ignore the original series invite on your calendar and use the link below to join.
๐๐ฉ๐๐๐ญ๐: We will provide a brief status update on these technical issues at the start of the call. We apologize for the inconvenience!
๐๐จ๐ซ๐ค๐ ๐ซ๐จ๐ฎ๐ฉ ๐๐๐๐ฌ: ๐ ๐ข๐ง๐๐ข๐ง๐ ๐๐จ๐ฎ๐ซ โ๐๐จ๐ฆ๐โ ๐ข๐ง ๐๐๐๐๐
With nearly 40 workgroups driving our mission forward, it can be hard to know where to dive in. Over the next few weeks, we are highlighting the Objectives and Key Results (OKRs) for various teams. Whether you are a veteran collaborator or a newcomer, this is the perfect opportunity to align your talents with our 2026 research goals.
๐๐ข๐ง๐ข-๐๐จ๐ฎ๐ซ๐ง๐๐ฅ ๐๐ฅ๐ฎ๐: ๐๐ญ๐๐ญ๐ข๐ง ๐๐๐ฏ๐๐ซ๐ฌ๐ ๐๐ฏ๐๐ง๐ญ๐ฌ
We will also discuss this recent Lancet publication (https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)01578-8/fulltext) that examines labeled adverse events for statins.
The Finding: Of 66 labeled events, the study found that only 4 had significant associations in randomized clinical trials.
The Impact: This connects to the OHDSI goal of โone drug-by-all outcomesโ and potentially motivates the need, both because many labeled events may not be real, but also because some of what has been shown from the trials may not have sufficient statistical power.
#JoinTheJourney